Details of the Drug Combinations

General Information of This Drug (ID: DMBFZ6L)

Drug Name
Remdesivir   DMBFZ6L
Synonyms L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Approved [1]
Ebola virus infection 1D60.0 Phase 1 [2]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [3]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Remdesivir + Chloroquine DCWP6Z7 Chloroquine Coronavirus Disease 2019 (COVID-19) (Cell Line: .) [4]
------------------------------------------------------------------------------------
15 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Remdesivir + Favipiravir DCEI7Q7 Favipiravir Complication of Medical Care [5]
Dexamethasone + Remdesivir DC04KK6 Dexamethasone COVID-19 [6]
Dexamethasone + Remdesivir DC1G9ZO Dexamethasone COVID-19 [6]
Dexamethasone + Remdesivir DC1JU99 Dexamethasone COVID-19 [6]
Dexamethasone + Remdesivir DCATDUW Dexamethasone COVID-19 [6]
Dexamethasone + Remdesivir DCDA2MP Dexamethasone COVID-19 [6]
Dexamethasone + Remdesivir DCHLP40 Dexamethasone COVID-19 [6]
Dexamethasone + Remdesivir DCSV7TT Dexamethasone COVID-19 [6]
Dexamethasone + Remdesivir DC4J5GI Dexamethasone COVID-19 [6]
Merimepodib + Remdesivir DC1BJAR Merimepodib COVID-19 [7]
Remdesivir + Hydroxychloroquine DC0FMOW Hydroxychloroquine SARS-CoV Infection [8]
Dexamethasone + Remdesivir DC6T8Z8 Dexamethasone COVID-19 Infection [9]
Dexamethasone + Remdesivir DCJ5K9R Dexamethasone Covid19 [10]
Remdesivir + Baricitinib DC7UJ5S Baricitinib COVID-19 [11]
Remdesivir + Favipiravir DCHWSKP Favipiravir Covid19 [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 DrugCom(s)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
4 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
5 ClinicalTrials.gov (NCT04727775) Antiviral Drugs on the Treatment of SARS-CoV-2
6 ClinicalTrials.gov (NCT04488081) I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
7 ClinicalTrials.gov (NCT04410354) Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
8 ClinicalTrials.gov (NCT04321616) The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients
9 ClinicalTrials.gov (NCT04784559) Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
10 ClinicalTrials.gov (NCT04832880) Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)
11 ClinicalTrials.gov (NCT04401579) Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
12 ClinicalTrials.gov (NCT04694612) Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal